“We achieved encouraging results, knowledge and experience in vaccine development from our prior research collaboration with Sanofi Pasteur (which is anticipated to end in October 2016) that we believe can be leveraged and built upon with other partners. During the collaboration, meaningful improvements were made to the C1 expression system to produce antigens of interest that Sanofi further tested in mice trials. The mice trial data indicated that the C1 produced antigen generated an equal or better immune response in mice than the industry standard antigen.”
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...
